Abstract 3362
Background
In the randomized phase III SELECT study, LEN demonstrated a significant prolongation of progression-free survival compared with placebo (PBO) in pts with RR-DTC. There was no significant difference in overall survival (OS) between LEN and PBO arms which was likely due to > 80% of pts on the PBO arm crossing over to open-label LEN treatment. This exploratory post hoc analysis investigated the impact of measurable lung metastasis on OS from the SELECT study.
Methods
The hazard ratio (HR) for OS (data cutoff, September 1, 2016) and the 95% CIs were estimated using the Cox proportional hazards model. The influence of various baseline characteristics on OS was analyzed using a multivariate analysis based on a Cox proportional hazards model. Subgroup analysis of OS was conducted based on maximum size of measurable lung metastasis (≥ 1 cm per RECIST 1.1) at baseline.
Results
In the overall population (392 pts), median OS of LEN (261 pts) and PBO (131 pts, with 115 pts crossed over to LEN) arms, were 40.3 months (M) and 34.5 M, respectively (hazard ratio [HR] 0.87, 95% CI 0.66 –1.15, P = 0.3170). In 306 pts with lung metastasis of ≥ 1.0 cm, significant prolongation of OS was observed with LEN (199 pts) compared with PBO (107 pts, with 95 pts crossed over to LEN) (HR 0.63, 95% CI 0.47–0.85, P = 0.0025). This was maintained after adjustment for baseline characteristics in the multivariate model. Similar trends of OS prolongation by LEN were observed in pts with lung metastasis of ≥ 1.5 cm, ≥ 2.0 cm, and 1.0–2.0 cm (Table).Table:
1862PD Overall survival by size of measurable lung metastasis at baseline
Lung Lesion | Number of Pts | Median OS (M) | HR | 95% CI | P Value | ||
---|---|---|---|---|---|---|---|
LEN | PBO | LEN | PBO | ||||
≥1.0 cm | 199 | 107 | 44.7 | 33.1 | 0.63 | 0.47 – 0.85 | 0.0025 |
≥1.5 cm | 150 | 84 | 44.1 | 22.3 | 0.63 | 0.45 – 0.89 | 0.0082 |
≥2.0 cm | 94 | 58 | 34.7 | 19.3 | 0.65 | 0.44 – 0.98 | 0.0383 |
1.0–2.0 cm | 105 | 49 | 49.2 | 38.6 | 0.63 | 0.40 – 0.99 | 0.0438 |
≥ 1 cm per RECIST 1.1
Conclusions
In pts with lung metastasis of ≥ 1.0 cm, LEN significantly prolonged OS compared to pts treated by PBO including those crossed over to LEN. This post-hoc analysis suggests that RR-DTC pts with lung metastasis could be candidates for targeted therapy.
Clinical trial identification
NCT01321554; Release date: December 30, 2016.
Editorial acknowledgement
Oxford PharmaGenesis, Newtown, PA, USA; Funded by Eisai Inc.
Legal entity responsible for the study
Eisai Inc. and Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.
Funding
Eisai Inc. and Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.
Disclosure
M. Tahara: Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Bayer; Honoraria (self), Advisory / Consultancy: Bristol-Myers Squibb; Honoraria (self), Research grant / Funding (institution): Eisai; Honoraria (self): Merck Serono; Honoraria (self): Takeda; Advisory / Consultancy, Research grant / Funding (institution): Boehringer-Ingelheim; Advisory / Consultancy: MSD; Advisory / Consultancy, Research grant / Funding (institution): Ono Pharmaceutical; Advisory / Consultancy, Research grant / Funding (institution): Pfizer; Research grant / Funding (institution): AstraZeneca; Research grant / Funding (institution): Merck Sharp & Dohme; Research grant / Funding (institution): NanoCarrier; Research grant / Funding (institution): Novartis. N. Kiyota: Honoraria (self), Research grant / Funding (institution): Ono Pharmaceutical; Honoraria (self), Research grant / Funding (institution): Bristol-Myers Squibb; Honoraria (self): Merck Serono; Honoraria (self), Research grant / Funding (institution): Astra-Zeneca; Honoraria (self), Research grant / Funding (institution): Eisai; Honoraria (self), Research grant / Funding (institution): Bayer; Research grant / Funding (institution): Pfizer; Research grant / Funding (institution): Chugai Pharmaceutical. A..O. Hoff: Research grant / Funding (institution): Eisai; Advisory / Consultancy, Research grant / Funding (institution): Bayer; Research grant / Funding (institution): Astra-Zeneca; Research grant / Funding (institution): Exelixis; Advisory / Consultancy: Genzyme. T.K. Owonikoko: Advisory / Consultancy, Research grant / Funding (institution): Novartis, Celgene, Bayer; Advisory / Consultancy, Research grant / Funding (institution): AstraZeneca/MedImmune, Abbvie; Advisory / Consultancy, Research grant / Funding (institution): G1 Therapeutics, Bristol-Myers Squibb; Advisory / Consultancy, Research grant / Funding (institution): Amgen, Loxo/Lilly; Research grant / Funding (institution): Astellas, Stemcentrx, Regeneron, Corvus Pharmaceuticals; Research grant / Funding (institution): United Therapeutics, Fujifilm, Pfizer; Research grant / Funding (institution): Aeglea Biotherapeutics, Incyte, Merck; Advisory / Consultancy: Sandoz, Eisai, Takeda, Seattle Genetics; Advisory / Consultancy: BerGenBio, PharmaMar, Boehringer Ingelheim; Advisory / Consultancy: EMD Serono, Xcovery; Advisory / Consultancy: Heron Pharmaceuticals, Armo BioSciences; Shareholder / Stockholder / Stock options: Cambium Oncology. C.E. Dutcus: Full / Part-time employment: Eisai Inc.. T. Suzuki: Full / Part-time employment: Eisai Co., Ltd. M. Ren: Full / Part-time employment: Eisai Inc.. S. Misir: Full / Part-time employment: Eisai Inc. L.J. Wirth: Advisory / Consultancy: Bayer; Advisory / Consultancy: Eisai; Advisory / Consultancy: Loxo; Advisory / Consultancy: Merck. All other authors have declared no conflicts of interest.
Resources from the same session
4991 - Relation between objective tumor shrinkage and progression-free survival (PFS) in the NETTER-1 population
Presenter: Marianne Pavel
Session: Poster Discussion – NETs and endocrine tumours
Resources:
Abstract
5796 - Phase I Study of CC-90011 in Patients With Advanced Solid Tumors (STs) and Relapsed/Refractory Non-Hodgkin Lymphoma (R/R NHL)
Presenter: Antoine Hollebecque
Session: Poster Discussion – NETs and endocrine tumours
Resources:
Abstract
3199 - SUNitinib with EVOfosfamide (TH-302) for G1/G2 metastatic pancreatic neuroendocrine tumours (pNETs) naïve for systemic treatment. The SUNEVO phase II trial of the Spanish Task Force Group for Neuroendocrine and Endocrine Tumours (GETNE)
Presenter: Enrique Grande
Session: Poster Discussion – NETs and endocrine tumours
Resources:
Abstract
Slides
5891 - New circulating biomarkers in Gastro-Entero-Pancreatic-Neuroendocrine-Tumors
Presenter: Martine Bocchini
Session: Poster Discussion – NETs and endocrine tumours
Resources:
Abstract
1590 - Longitudinal Increase in Ki67 and High-grade Transformation in Pancreatic Neuroendocrine Tumors (PNETs)
Presenter: Johan Botling
Session: Poster Discussion – NETs and endocrine tumours
Resources:
Abstract
3665 - Prescription and Treatment Patterns of Lenvatinib (L) in Patients with Radioactive Iodine-Refractory Differentiated Thyroid Cancer (rDTC): A Retrospective Analysis of the Canadian Patient Support Program (PSP)
Presenter: Sebastien Hotte
Session: Poster Discussion – NETs and endocrine tumours
Resources:
Abstract
5072 - Spatiotemporal intratumor genetic heterogeneity and clonal evolution in PTCs and paired DM
Presenter: Sara Gil Bernabé
Session: Poster Discussion – NETs and endocrine tumours
Resources:
Abstract
2034 - Specific patterns of long non-coding RNA expression in benign and malignant thyroid nodules
Presenter: Valentina Yakushina
Session: Poster Discussion – NETs and endocrine tumours
Resources:
Abstract
Poster Discussion – NETs and endocrine tumours - Invited Discussant 1382PD, 1383PD and 1834PD
Presenter: Nicola Fazio
Session: Poster Discussion – NETs and endocrine tumours
Resources:
Slides
Webcast
Poster Discussion – NETs and endocrine tumours - Invited Discussant 1385PD and 1386PD
Presenter: Rocio Garcia-Carbonero
Session: Poster Discussion – NETs and endocrine tumours
Resources:
Slides
Webcast